Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with metastatic non-small cell lung cancer (a type of lung cancer that has spread to other parts of the body) — for Cohorts 1A and 1B.
- People who have been diagnosed with resectable head and neck squamous cell carcinoma (a type of head and neck cancer that surgeons consider removable) — for Cohorts 2A and 2B.
- People who are aged 18 or older at the time of joining the trial.
- People who are willing and able to follow the study procedures, as assessed by the trial investigator.
- People who have provided written consent to participate and agreed to the release of their personal health information as required by the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently taking steroid medications (such as prednisone at a dose of 10 mg or more, or an equivalent dose of another steroid) that cannot be stopped at least 7 days before starting standard treatment.
- People who received certain immune checkpoint therapy treatments (a type of cancer immunotherapy targeting PD-1, PD-L1, or CTLA-4) within the 6 months before the screening visit.
- People who are currently taking part in another clinical trial that involves a treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shetal A Patel, MD, UNC Lineberger Comprehensive Cancer Center
Phone: 919-984-0000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression free survival (PFS) - non-small cell lung cancer (NSCLC); Major Pathologic Response (MPR) -head and neck squamous cell carcinoma (HNSCC).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.